that gene. These individuals have a markedly lower incidence of Alzheimer's than those who carry the E4 gene. The new study found that ApoE4 produced more protein fragments than did E2 or E3.
"ApoE4 apparently interacts better with the receptor than its cousins," said Tang. "This may explain why people who carry the E4 gene have a higher risk of developing Alzheimer's."
"These findings may allow us to investigate the possibility of therapeutic intervention at different points in the process," said Tang. For example, he said, such efforts might focus on developing a compound to interfere with the receptor's ability to adhere to ApoE4.
"There currently is no effective treatment for Alzheimer's disease, so we must explore every possible option to find a way to stop it," he said.
"Dr. Tang's study shows a beautiful biochemical connection between a genetic risk factor and the development of a disease," said OMRF President Stephen Prescott, M.D. "This work opens the door to the development of alternate methods for treatingand perhaps even preventingAlzheimer's."
ApoE4 also has been linked to coronary artery disease. "Ultimately, this work could pave the way for similar study of the pathogenesis of other diseases," said Prescott.
Contact: Shari Hawkins
Oklahoma Medical Research Foundation 10-Apr-2007Page: 1 2 Related biology news :1
. New study warns limited carbon market puts 20 percent of tropical forest at risk2
. Clones on task serve greater good, evolutionary study shows3
. Pollution causes 40 percent of deaths worldwide, study finds4
. A study by the MUHC and McGill University opens a new door to understanding cancer5
. New study suggests Concord grape juice may provide protection against breast cancer6
. Preclinical study links gene to brain aneurysm formation7
. In limiting life span, study finds booming bacteria innocent8
. Multicenter study nets new lung tumor-suppressor gene9
. MIT study: Maturity brings richer memories10
. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study11
. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer